(Q39388076)

11 September 2017

title

Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period (English)

1 reference

11 September 2017

Montelukast improves symptoms of seasonal allergic rhinitis over a 4‐week treatment period (English)

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

1 April 2024

1 reference

seasonal allergic rhinitis

1 reference

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

1 April 2024

author name string

Montelukast Fall Rhinitis Study Group

8

1 reference

11 September 2017

J. van Adelsberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616102

1 April 2024

G. Philip

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616102

1 April 2024

A. J. Pedinoff

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616102

1 April 2024

E. O. Meltzer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616102

1 April 2024

P. H. Ratner

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616102

1 April 2024

J. Menten

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616102

1 April 2024

T. F. Reiss

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616102

1 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14616102

1 April 2024

publication date

1 December 2003

1 reference

full work available at URL

11 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1398-9995.2003.00261.x

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1398-9995.2003.00261.x

1 April 2024

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

1 April 2024

1 reference

11 September 2017

volume

58

1 reference

11 September 2017

issue

12

1 reference

11 September 2017

page(s)

1268-1276

1 reference

American Thoracic Society Workshop. Immunobiology of asthma and rhinitis. Pathogenic factors and therapeutic options

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1398-9995.2003.00261.X

Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease".

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Allergic rhinitis and its impact on asthma

1 April 2024

3

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial

1 April 2024

5

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall

1 April 2024

6

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring

1 April 2024

7

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults

1 April 2024

8

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group

1 April 2024

9

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Antiallergic effects of H1-receptor antagonists

1 April 2024

11

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis.

1 April 2024

12

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Measuring health-related quality of life in rhinitis

1 April 2024

13

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years

1 April 2024

14

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis

1 April 2024

15

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents

1 April 2024

16

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Nasal physiology and inflammatory mediators during natural pollen exposure

1 April 2024

18

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Comparison of the secretory response of the nasal mucosa to methacholine and histamine.

1 April 2024

19

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Effect of magnitude of airway responsiveness and therapy with inhaled corticosteroid on histamine tachyphylaxis in asthma

1 April 2024

20

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis

1 April 2024

21

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Nasal response to a single antigen challenge in patients with allergic rhinitis - inflammatory cell recruitment persists up to 48 hours

1 April 2024

22

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure

1 April 2024

23

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

Basophil histamine release, IgE, eosinophil counts, ECP, and EPX are related to the severity of symptoms in seasonal allergic rhinitis

1 April 2024

24

1 reference

https://api.crossref.org/works/10.1046/J.1398-9995.2003.00261.X

1 April 2024

Identifiers

1 reference

11 September 2017

1 reference